---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-004085"
form_type: "8-K"
ticker: "PSNL"
cik: "0001527753"
company_name: "Personalis, Inc."
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T02:32:16.618824+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Personalis reports Q4 2022 revenue $16.7M, net loss $31.1M; guides FY2023 revenue $68-72M

## Summary
- Q4 2022 revenue $16.7M, full year $65.0M; net loss Q4 $31.1M ($0.67/share), full year $113.3M ($2.48/share).
- Cash and investments $167.7M at Dec 31, 2022; FY2023 cash usage guided to ~$75M, down from $119M in 2022.
- Partnership with Moderna for genomic testing in personalized cancer vaccine trials; MRD validation study with Criterium and ABRCC.
- Strategic review completed; new focus on MRD, personalized cancer vaccines, and pharma clinical trial support.
- FY2023 net loss guided to ~$103M, improved from $113M in 2022 due to headcount reduction savings.

## SEC filing metadata
- accession: 0000950170-23-004085
- form_type: 8-K
- ticker: PSNL
- cik: 0001527753
- company_name: Personalis, Inc.
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527753/000095017023004085/0000950170-23-004085-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527753/000095017023004085/psnl-20230223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-004085
- JSON: https://secwatch.observer/filing/0000950170-23-004085.json
- Plain text: https://secwatch.observer/filing/0000950170-23-004085.txt

## Key facts
- Earnings Releases
  Personalis, Inc. reported the fourth quarter and full year ended December 31, 2022 results: revenue $16.7 million for the fourth quarter of 2022 and $65.0 million for the full year of 2022, net income Net loss of $31.1 million, and net loss per share of $0.67 ... in the fourth quarter 2022; net loss of $113.3 million, a, EPS $0.67 ... in the fourth quarter 2022; ... $2.48 ... in the full year 2022. Guidance initiated.
  - Period: the fourth quarter and full year ended December 31, 2022
  - Revenue: $16.7 million for the fourth quarter of 2022 and $65.0 million for the full year of 2022
  - Net income: Net loss of $31.1 million, and net loss per share of $0.67 ... in the fourth quarter 2022; net loss of $113.3 million, a
  - EPS: $0.67 ... in the fourth quarter 2022; ... $2.48 ... in the full year 2022
  - Guidance: initiated
  - Result: reported results
  source text: Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1527753/000095017023004085/0000950170-23-004085-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.